SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis
Ilias Bensouna, Valérie Caudwell, Sabah Kubab, Sandra Acquaviva, Agathe Pardon, Nathalie Vittoz, Dogan-Firat Bozman, Latifa Hanafi, Anne-Laure Faucon, Pierre Housset, Ilias Bensouna, Valérie Caudwell, Sabah Kubab, Sandra Acquaviva, Agathe Pardon, Nathalie Vittoz, Dogan-Firat Bozman, Latifa Hanafi, Anne-Laure Faucon, Pierre Housset
Abstract
Rationale & objective: Recent studies showed that antibody titers after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the dialysis population are diminished as compared with the general population, suggesting the possible value of a third booster dose. We characterized the humoral response after 3 doses of the BNT162b2 vaccine in patients treated with either maintenance hemodialysis (HD) or peritoneal dialysis (PD).
Study design: Case series.
Setting & participants: 69 French patients (38 HD and 31 PD) treated at a single center who received 3 doses of the BNT162b2 vaccine.
Findings: Humoral response was evaluated using plasma levels of anti-SARS-CoV-2 spike protein S1 immunoglobulin measured after the second dose and at least 3 weeks after the third dose of the BNT162b2 vaccine. Patients (median age 68 years [interquartile range (IQR), 53-76 years], 65% men) had a median anti-S1 antibody level of 284 [IQR, 83-1190] AU/mL after the second dose, and 7,554 [IQR, 2,268-11,736] AU/mL after the third dose. Three patients were nonresponders (anti-S1 antibody level < 0.8 AU/mL), and 12 were weak responders (anti-S1 antibody level 0.8-50 AU/mL) after the second vaccine dose. After the third dose, 1 of the 3 initial nonresponders produced anti-spike antibody, and all the 12 initial weak responders increased their antibody levels. Patients with a greater increase in anti-S1 antibody levels after a third dose had lower antibody levels after the second dose, and a longer time interval between the second and the third dose. Adverse events did not seem to be more common or severe after a third vaccine dose.
Limitations: Observational study, small sample size. Relationship between antibody levels and clinical outcomes is not well understood.
Conclusions: A third dose of the BNT162b2 vaccine substantially increased antibody levels in patients receiving maintenance dialysis and appeared to be as well tolerated as a second dose.
Keywords: Antibody levels; BNT162b2; anti-spike serology; coronavirus disease 2019 (COVID-19); dialysis; end-stage renal disease (ESRD); immune response; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); third booster dose; vaccine; vaccine adverse effects.
Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Figures
References
- Shimada N., Shimada H., Itaya Y., Tomino Y. Novel coronavirus disease in patients with end-stage kidney disease. Ther Apher Dial. 2021;25(5):544–550. doi: 10.1111/1744-9987.13599.
- Meziyerh S., Helm D., Vries A.P.J. Vulnerabilities in kidney transplant recipients with COVID-19: a single center experience. Transpl Int. 2020;33(11):1557–1561. doi: 10.1111/tri.13714.
- Nikoskelainen J., Koskela M., Forsström J., Kasanen A., Leinonen M. Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney Int. 1985;28(4):672–677. doi: 10.1038/ki.1985.182.
- Pitchou Y Kengibe, Jean-Robert R Makulo, Yannick M Nlandu, et al. Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study. Pan Afr Med J. 2019;34:122. doi: 10.11604/pamj.2019.34.122.19603.
- Crépin T., Legendre M., Courivaud C., et al. Premature immune senescence and chronic kidney disease: update and perspectives. Article in French. Nephrol Ther. 2020;16(1):9–18. doi: 10.1016/j.nephro.2019.04.005.
- Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577.
- Grupper A, Sharon N, Finn T, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. Published online April 6, 2021.
- Ikizler T.A., Coates P.T., Rovin B.H., Ronco P. Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Kidney Int. 2021;99(6):1275–1279. doi: 10.1016/j.kint.2021.04.007.
- Torreggiani M., Blanchi S., Fois A., Fessi H., Piccoli G.B. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney Int. 2021;99(6):1494–1496. doi: 10.1016/j.kint.2021.04.010.
- Attias P., Sakhi H., Rieu P., et al. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int. 2021;99(6):1490–1492. doi: 10.1016/j.kint.2021.04.009.
- Yanay N.B., Freiman S., Shapira M., et al. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients. Kidney Int. 2021;99(6):1496–1498. doi: 10.1016/j.kint.2021.04.006.
- Agur T, Ben-Dor N, Goldman S, et al. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study. Nephrol Dial Transplant. Published online April 11, 2021.
- Simon B, Rubey H, Treipl A, et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls. Nephrol Dial Transplant. Published online May 17, 2021.
- Centre opérationnel de régulation et de réponse aux urgences sanitaires et sociales (CORRUSS) DGS-Urgent No. 2021-43. Vaccins contre la Covid-19: modalites d’administration des rappels. April 11, 2021.
- Werbel W.A., Boyarsky B.J., Ou M.T., et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. 2021;174(9):1330–1332. doi: 10.7326/L21-0282.
- Kamar N., Abravanel F., Marion O., Couat C., Izopet J., Del Bello A. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661–662. doi: 10.1056/NEJMc2108861.
- Frantzen L, Thibeaut S, Moussi-Frances J, et al. COVID-19 Vaccination in haemodialysis patients: good things come in threes. Nephrol Dial Transplant. Published online July 20, 2021.
- Mueller T. Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: a method comparison of two different commercially available serological assays from the same manufacturer. Clin Chim Acta. 2021;518:9–16. doi: 10.1016/j.cca.2021.03.007.
- Bird S., Panopoulou A., Shea R.L., et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;8(6):e389–e392. doi: 10.1016/S2352-3026(21)00110-1.
- Sakhi H., Dahmane D., Attias P., et al. Kinetics of anti–SARS-CoV-2 IgG antibodies in hemodialysis patients six months after infection. J Am Soc Nephrol. 2021;32(5):1033–1036. doi: 10.1681/ASN.2020111618.
- Clarke C.L., Prendecki M., Dhutia A., et al. Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. Kidney Int. 2021;99(6):1470–1477. doi: 10.1016/j.kint.2021.03.009.
- Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. Published online July 20, 2021.
- Lumley S.F., O’Donnell D., Stoesser N.E., et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2020;384(6):533–540. doi: 10.1056/NEJMoa2034545.
- Joyner M.J., Carter R.E., Senefeld J.W., et al. Convalescent plasma antibody levels and the risk of death from COVID-19. N Engl J Med. 2021;384(11):1015–1027. doi: 10.1056/NEJMoa2031893.
- Broseta J.J., Rodríguez-Espinosa D., Rodríguez N., et al. Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients. Am J Kidney Dis. 2021;78(4):571–681.
- Hu Y., Xu L., Wang X., et al. Changes before and after COVID-19 pandemic on the personal hygiene behaviors and incidence of peritonitis in peritoneal-dialysis patients: a multi-center retrospective study. Int Urol Nephrol. Published online June 19, 2021 doi: 10.1007/s11255-021-02924-5.
- Day M. COVID-19: Stronger warnings are needed to curb socialising after vaccination, say doctors and behavioural scientists. BMJ. 2021;372:n783. doi: 10.1136/bmj.n783.
Source: PubMed